31.07.2023 - Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, and Incyte (NASDAQ:INCY), a global biopharmaceutical company, today announced a . Seite 1
Incyte (INCY) and Replimune (REPL) Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Incyte (INCY) And Mirati (MRTX) Enters Collaboration and Supply Agreement to Evaluate INCB99280 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
DGAP-News: MorphoSys AG / Key word: Agreement/Miscellaneous
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion. | June 13, 2022
DGAP-News: MorphoSys AG / Key word(s): Agreement/MiscellaneousPfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47 13.06.2022 / 22:01 The issuer is solely responsible for the content of this announceme.